Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASM8-003 in mild allergic asthma
NCT00264966Phase 2Completed
- Sponsor
- Syntara Limited
- Start
- Dec 2005
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ASM8 in asthma (2 arms), sponsored by Syntara Limited. Primary endpoint: Late Asthmatic Response. Started Dec 2005; status: completed.
02
Drugs
ASM8
03
Conditions
asthma
Beyond the preview
Go deeper on NCT00264966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00264966.